ArticleACR open rheumatology2020

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial.

Paul Emery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.